In addition, in the United States, the transmission of poliovirus, measles and rubella have been eliminated. These are examples of tremendous scientific progress, and through our growing understanding of how these and other diseases work at the molecular level, many new therapeutic and preventative vaccines have been developed.
A new PhRMA report, “Medicines in Development for Vaccines,” offers insight into the more than 250 vaccines currently in development, designed to prevent and treat illness.
More than two-thirds of the vaccines in the last 25 years have been developed in the United States – underscoring the commitment of America’s biopharmaceutical research companies despite a particularly challenging research and development process.
Vaccines in development today will help prevent or treat a number of conditions, including:
· 124 for infectious diseases; and
· 105 for cancer.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.
Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
To visit PhRMA’s information-packed, consumer-friendly blog about the innovation-driven biopharmaceutical industry, The Catalyst, click here.